Indications |
Intramuscular Uncomplicated gonorrhoea Adult: 250 mg as a single dose.
Intramuscular Prophylaxis of secondary meningococcal meningitis Adult: 250 mg as a single dose. Child: 125 mg as a single dose. Max Dosage:
Parenteral Susceptible infections Adult: 1-2 g daily as a single or in 2 divided doses given as deep IM inj or slow IV inj over 2-4 minutes or as infusion over at least 30 minutes, increased to 4 g daily in severe infections. Child: <50 kg: 25-50 mg/kg once daily increased to 80 mg/kg in severe infections. Doses >50 mg/kg should be given as IV infusion. IV infusion in neonates should be given over 60 min. Max dose (neonates): 50 mg/kg/day.
Parenteral Prophylaxis of surgical infections Adult: 1 g as a single dose given 0.5-2 hr prior to surgery via deep IM inj or slow IV inj over at least 2-4 minutes or IV infusion over at least 30 minutes. A 2 g dose is recommended for colorectal surgery.
Intravenous Typhoid fever Adult: 2 g once daily for 14 days.
Special Populations: Reduce dose in patients with severe renal impairment and those with both renal and hepatic impairment. Incompatibility: Y-site incompatibility: Alatrofloxacin, amphotericin B cholesteryl sulfate complex, pentamidine, parenteral nutrition solutions (containing calcium), amsacrine, azithromycin, calcium, filgrastim, fluconazole, Hartmann's solution, labetalol, vinorelbine. Admixture incompatibility: Aminophylline, amsacrine, fluconazole, linezolid, calcium, clindamycin, theophylline. |
||||||||||||||||||||
Contraindications |
Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation. | ||||||||||||||||||||
Warnings / Precautions |
History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection. | ||||||||||||||||||||
Adverse Reactions |
Superinfection; anaphylaxis; diarrhoea; local reactions; blood dyscrasias; rash, fever, pruritus; elevated transaminases and alkaline phosphatase; leucopenia, neutropenia. Potentially Fatal: Pseudomembranous colitis; nephrotoxicity. |
||||||||||||||||||||
Drug Interactions |
Disulfiram-like reaction with alcohol. Potentially Fatal: Nephrotoxicity with aminoglycosides and furosemide. See Below for More ceftriaxone Drug Interactions |
||||||||||||||||||||
Lab Interactions |
May interfere with urinary glucose test. False-positive Coomb's test. | ||||||||||||||||||||
Mechanism of Actions |
Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Absorption: Peak plasma concentrations after 2 hr (IM). Distribution: Distributed widely into body tissues and fluids; CSF (therapeutic concentrations). Crosses the placenta and enters breast milk; bile (high concentrations). Protein-binding: 85-95%. Excretion: Via the urine (40-65% as unchanged); via the bile to the faeces (remainder as unchanged and microbiologically inactive compounds); 6-9 hr (elimination half-life). |
||||||||||||||||||||
Storage Conditions |
Intramuscular: Store below 25°C. Intravenous: Store below 25°C. Parenteral: Store at 25°C. | ||||||||||||||||||||
ATC Classification |
J01DD04 - ceftriaxone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections. | ||||||||||||||||||||
Storage |
Intramuscular: Store below 25°C. Intravenous: Store below 25°C. Parenteral: Store at 25°C. | ||||||||||||||||||||
Available As |
|
Ceftriaxone
Post Review about Ceftriaxone Click here to cancel reply.
Ceftriaxone Containing Brands
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.